Effects of resveratrol in experimental and clinical non-alcoholic fatty liver disease

World Journal of Hepatology

Volumn 6, Issue 4, 2014, Pages 188-198

  Heebøll, Sara ^a   Thomsen, Karen Louise ^a   Pedersen, Steen B ^a   Vilstrup, Hendrik ^a   George, Jacob ^b   Grønbæk, Henning ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

AMPactivated protein kinase; Animal studies; Anti inflammatory agents; Anti oxidants; Clinical trial; Non alcoholic fatty liver disease; Nonalcoholic steatohepatitis; Resveratrol; Silent information regulation 2 homolog 1; Steatosis

Indexed keywords

EID: 84901188426     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v6.i4.188     Document Type: Review

References (120)

1. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34: 274-285 [PMID: 21623852 DOI: 10.1111/j.1365-2036.2011.04724.x]
2. Welsh JA, Karpen S, Vos MB. Increasing prevalence of nonalcoholic fatty liver disease among United States adolescents, 1988-1994 to 2007-2010. J Pediatr 2013; 162: 496-500.e1 [PMID: 23084707 DOI: 10.1016/j.jpeds.2012.08.043]
3. Bloomgarden ZT. Nonalcoholic fatty liver disease and insulin resistance in youth. Diabetes Care 2007; 30: 1663-1669 [PMID: 17526824 DOI: 10.2337/dc07-zb06]
4. Kopec KL, Burns D. Nonalcoholic fatty liver disease: a review of the spectrum of disease, diagnosis, and therapy. Nutr Clin Pract 2011; 26: 565-576 [PMID: 21947639 DOI: 10.1177/0884533611419668]
5. Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011; 141: 1249-1253 [PMID: 21726509 DOI: 10.1053/j.gastro.2011.06.061]
6. Schuppan D, Gorrell MD, Klein T, Mark M, Afdhal NH. The challenge of developing novel pharmacological therapies for non-alcoholic steatohepatitis. Liver Int 2010; 30: 795-808 [PMID: 20624207 DOI: 10.1111/j.1478-3231.2010.02264.x]
7. Wing RR, Phelan S. Long-term weight loss maintenance. Am J Clin Nutr 2005; 82: 222S-225S [PMID: 16002825]
8. Tanner BD, Allen JW. Complications of bariatric surgery: implications for the covering physician. Am Surg 2009; 75: 103-112 [PMID: 19280802]
9. Klein EA, Thompson IM, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, Minasian LM, Ford LG, Parnes HL, Gaziano JM, Karp DD, Lieber MM, Walther PJ, Klotz L, Parsons JK, Chin JL, Darke AK, Lippman SM, Goodman GE, Meyskens FL, Baker LH. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2011; 306: 1549-1556 [PMID: 21990298 DOI: 10.1001/ jama.2011.1437]
10. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst Rev 2012; 3: CD007176 [PMID: 22419320 DOI: 10.1002/14651858.CD007176.pub2]
11. Kung J, Henry RR. Thiazolidinedione safety. Expert Opin Drug Saf 2012; 11: 565-579 [PMID: 22616948 DOI: 10.1517/14 740338.2012.691963]
12. Kostapanos MS, Kei A, Elisaf MS. Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease. World J Hepatol 2013; 5: 470-478 [PMID: 24073298 DOI: 10.4254/wjh.v5.i9.470]
13. Hatzis G, Ziakas P, Kavantzas N, Triantafyllou A, Sigalas P, Andreadou I, Ioannidis K, Chatzis S, Filis K, Papalampros A, Sigala F. Melatonin attenuates high fat diet-induced fatty liver disease in rats. World J Hepatol 2013; 5: 160-169 [PMID: 23671720 DOI: 10.4254/wjh.v5.i4.160]
14. Kelishadi R, Farajian S, Mirlohi M. Probiotics as a novel treatment for non-alcoholic Fatty liver disease; a systematic review on the current evidences. Hepat Mon 2013; 13: e7233 [PMID: 23885277 DOI: 10.5812/hepatmon.7233]
15. Tomeno W, Yoneda M, Imajo K, Ogawa Y, Kessoku T, Saito S, Eguchi Y, Nakajima A. Emerging drugs for non-alcoholic steatohepatitis. Expert Opin Emerg Drugs 2013; 18: 279-290 [PMID: 23848366 DOI: 10.1517/14728214.2013.811232]
16. Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, Zipkin RE, Chung P, Kisielewski A, Zhang LL, Scherer B, Sinclair DA. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003; 425: 191-196 [PMID: 12939617 DOI: 10.1038/nature01960]
17. Zang M, Xu S, Maitland-Toolan KA, Zuccollo A, Hou X, Jiang B, Wierzbicki M, Verbeuren TJ, Cohen RA. Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptordeficient mice. Diabetes 2006; 55: 2180-2191 [PMID: 16873680 DOI: 10.2337/db05-1188]
18. Smith JJ, Kenney RD, Gagne DJ, Frushour BP, Ladd W, Galonek HL, Israelian K, Song J, Razvadauskaite G, Lynch AV, Carney DP, Johnson RJ, Lavu S, Iffland A, Elliott PJ, Lambert PD, Elliston KO, Jirousek MR, Milne JC, Boss O. Small molecule activators of SIRT1 replicate signaling pathways triggered by calorie restriction in vivo. BMC Syst Biol 2009; 3: 31 [PMID: 19284563 DOI: 10.1186/1752-0509-3-31]
19. Price NL, Gomes AP, Ling AJ, Duarte FV, Martin-Montalvo A, North BJ, Agarwal B, Ye L, Ramadori G, Teodoro JS, Hubbard BP, Varela AT, Davis JG, Varamini B, Hafner A, Moaddel R, Rolo AP, Coppari R, Palmeira CM, de Cabo R, Baur JA, Sinclair DA. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab 2012; 15: 675-690 [PMID: 22560220 DOI: 10.1016/j.cmet.2012.04.003]
20. Um JH, Park SJ, Kang H, Yang S, Foretz M, McBurney MW, Kim MK, Viollet B, Chung JH. AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes 2010; 59: 554-563 [PMID: 19934007 DOI: 10.2337/db09-0482]
21. Park SJ, Ahmad F, Philp A, Baar K, Williams T, Luo H, Ke H, Rehmann H, Taussig R, Brown AL, Kim MK, Beaven MA, Burgin AB, Manganiello V, Chung JH. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 2012; 148: 421-433 [PMID: 22304913 DOI: 10.1016/j.cell.2012.01.017]
22. Haukeland JW, Konopski Z, Eggesbø HB, von Volkmann HL, Raschpichler G, Bjøro K, Haaland T, Løberg EM, Birkeland K. Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. Scand J Gastroenterol 2009; 44: 853-860 [PMID: 19811343 DOI: 10.1080/0036552090 2845268]
23. Omer Z, Cetinkalp S, Akyildiz M, Yilmaz F, Batur Y, Yilmaz C, Akarca U. Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2010; 22: 18-23 [PMID: 19667999 DOI: 10.1097/ MEG.0b013e32832e2baf]
24. Musso G, Gambino R, Cassader M, Pagano G. A metaanalysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010; 52: 79-104 [PMID: 20578268 DOI: 10.1002/hep.23623]
25. Yang YM, Han CY, Kim YJ, Kim SG. AMPK-associated signaling to bridge the gap between fuel metabolism and hepatocyte viability. World J Gastroenterol 2010; 16: 3731-3742 [PMID: 20698033 DOI: 10.3748/wjg.v16.i30.3731]
26. Viollet B, Athea Y, Mounier R, Guigas B, Zarrinpashneh E, Horman S, Lantier L, Hebrard S, Devin-Leclerc J, Beauloye C, Foretz M, Andreelli F, Ventura-Clapier R, Bertrand L. AMPK: Lessons from transgenic and knockout animals. Front Biosci (Landmark Ed) 2009; 14: 19-44 [PMID: 19273052]
27. Alberdi G, Rodríguez VM, Macarulla MT, Miranda J, Churruca I, Portillo MP. Hepatic lipid metabolic pathways modified by resveratrol in rats fed an obesogenic diet. Nutrition 2013; 29: 562-567 [PMID: 23274094 DOI: 10.1016/ j.nut.2012.09.011]
28. Li Y, Xu S, Mihaylova MM, Zheng B, Hou X, Jiang B, Park O, Luo Z, Lefai E, Shyy JY, Gao B, Wierzbicki M, Verbeuren TJ, Shaw RJ, Cohen RA, Zang M. AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metab 2011; 13: 376-388 [PMID: 21459323 DOI: 10.1016/ j.cmet.2011.03.009]
29. Henriksen BS, Curtis ME, Fillmore N, Cardon BR, Thomson DM, Hancock CR. The effects of chronic AMPK activation on hepatic triglyceride accumulation and glycerol 3-phosphate acyltransferase activity with high fat feeding. Diabetol Metab Syndr 2013; 5: 29 [PMID: 23725555 DOI: 10.1186/1758-5996-5-29]
30. Hou X, Xu S, Maitland-Toolan KA, Sato K, Jiang B, Ido Y, Lan F, Walsh K, Wierzbicki M, Verbeuren TJ, Cohen RA, Zang M. SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase. J Biol Chem 2008; 283: 20015-20026 [PMID: 18482975]
31. Schug TT, Li X. Sirtuin 1 in lipid metabolism and obesity. Ann Med 2011; 43: 198-211 [PMID: 21345154 DOI: 10.3109/07 853890.2010.547211]
32. Kaeberlein M, McVey M, Guarente L. The SIR2/3/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms. Genes Dev 1999; 13: 2570-2580 [PMID: 10521401]
33. Tissenbaum HA, Guarente L. Increased dosage of a sir-2 gene extends lifespan in Caenorhabditis elegans. Nature 2001; 410: 227-230 [PMID: 11242085 DOI: 10.1038/35065638]
34. Rogina B, Helfand SL. Sir2 mediates longevity in the fly through a pathway related to calorie restriction. Proc Natl Acad Sci USA 2004; 101: 15998-16003 [PMID: 15520384 DOI: 10.1073/pnas.0404184101]
35. Herranz D, Serrano M. Impact of Sirt1 on mammalian aging. Aging (Albany NY) 2010; 2: 315-316 [PMID: 20562473]
36. Purushotham A, Schug TT, Xu Q, Surapureddi S, Guo X, Li X. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab 2009; 9: 327-338 [PMID: 19356714 DOI: 10.1016/ j.cmet.2009.02.006]
37. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, Prabhu VV, Allard JS, Lopez-Lluch G, Lewis K, Pistell PJ, Poosala S, Becker KG, Boss O, Gwinn D, Wang M, Ramaswamy S, Fishbein KW, Spencer RG, Lakatta EG, Le Couteur D, Shaw RJ, Navas P, Puigserver P, Ingram DK, de Cabo R, Sinclair DA. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006; 444: 337-342 [PMID: 17086191 DOI: 10.1038/nature05354]
38. Li X, Zhang S, Blander G, Tse JG, Krieger M, Guarente L. SIRT1 deacetylates and positively regulates the nuclear receptor LXR. Mol Cell 2007; 28: 91-106 [PMID: 17936707 DOI: 10.1016/j.molcel.2007.07.032]
39. Kemper JK, Xiao Z, Ponugoti B, Miao J, Fang S, Kanamaluru D, Tsang S, Wu SY, Chiang CM, Veenstra TD. FXR acetylation is normally dynamically regulated by p300 and SIRT1 but constitutively elevated in metabolic disease states. Cell Metab 2009; 10: 392-404 [PMID: 19883617 DOI: 10.1016/ j.cmet.2009.09.009]
40. Ponugoti B, Kim DH, Xiao Z, Smith Z, Miao J, Zang M, Wu SY, Chiang CM, Veenstra TD, Kemper JK. SIRT1 deacetylates and inhibits SREBP-1C activity in regulation of hepatic lipid metabolism. J Biol Chem 2010; 285: 33959-33970 [PMID: 20817729 DOI: 10.1074/jbc.M110.122978]
41. Walker AK, Yang F, Jiang K, Ji JY, Watts JL, Purushotham A, Boss O, Hirsch ML, Ribich S, Smith JJ, Israelian K, Westphal CH, Rodgers JT, Shioda T, Elson SL, Mulligan P, Najafi-Shoushtari H, Black JC, Thakur JK, Kadyk LC, Whetstine JR, Mostoslavsky R, Puigserver P, Li X, Dyson NJ, Hart AC, Näär AM. Conserved role of SIRT1 orthologs in fastingdependent inhibition of the lipid/cholesterol regulator SREBP. Genes Dev 2010; 24: 1403-1417 [PMID: 20595232 DOI: 10.1101/gad.1901210]
42. Rodgers JT, Puigserver P. Fasting-dependent glucose and lipid metabolic response through hepatic sirtuin 1. Proc Natl Acad Sci USA 2007; 104: 12861-12866 [PMID: 17646659 DOI: 10.1073/pnas.0702509104] 43 Xie J, Zhang X, Zhang L. Negative regulation of inflammation by SIRT1. Pharmacol Res 2013; 67: 60-67 [PMID: 23098819 DOI: 10.1016/j.phrs.2012.10.010]
43. Xie J, Zhang X, Zhang L. Negative regulation of inflammation by SIRT1. Pharmacol Res 2013; 67: 60-67 [PMID: 23098819 DOI: 10.1016/j.phrs.2012.10.010]
44. Rivera L, Morón R, Zarzuelo A, Galisteo M. Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. Biochem Pharmacol 2009; 77: 1053-1063 [PMID: 19100718 DOI: 10.1016/ j.bcp.2008.11.027]
45. Kim S, Jin Y, Choi Y, Park T. Resveratrol exerts anti-obesity effects via mechanisms involving down-regulation of adipogenic and inflammatory processes in mice. Biochem Pharmacol 2011; 81: 1343-1351 [PMID: 21439945 DOI: 10.1016/ j.bcp.2011.03.012]
46. Kang W, Hong HJ, Guan J, Kim DG, Yang EJ, Koh G, Park D, Han CH, Lee YJ, Lee DH. Resveratrol improves insulin signaling in a tissue-specific manner under insulin-resistant conditions only: in vitro and in vivo experiments in rodents. Metabolism 2012; 61: 424-433 [PMID: 21945106 DOI: 10.1016/ j.metabol.2011.08.003]
47. Cullberg KB, Olholm J, Paulsen SK, Foldager CB, Lind M, Richelsen B, Pedersen SB. Resveratrol has inhibitory effects on the hypoxia-induced inflammation and angiogenesis in human adipose tissue in vitro. Eur J Pharm Sci 2013; 49: 251-257 [PMID: 23466666 DOI: 10.1016/j.ejps.2013.02.014]
48. Gonzales AM, Orlando RA. Curcumin and resveratrol inhibit nuclear factor-kappaB-mediated cytokine expression in adipocytes. Nutr Metab (Lond) 2008; 5: 17 [PMID: 18549505 DOI: 10.1186/1743-7075-5-17]
49. Bujanda L, Hijona E, Larzabal M, Beraza M, Aldazabal P, García-Urkia N, Sarasqueta C, Cosme A, Irastorza B, González A, Arenas JI. Resveratrol inhibits nonalcoholic fatty liver disease in rats. BMC Gastroenterol 2008; 8: 40 [PMID: 18782455 DOI: 10.1186/1471-230X-8-40]
50. Do GM, Jung UJ, Park HJ, Kwon EY, Jeon SM, McGregor RA, Choi MS. Resveratrol ameliorates diabetes-related metabolic changes via activation of AMP-activated protein kinase and its downstream targets in db/db mice. Mol Nutr Food Res 2012; 56: 1282-1291 [PMID: 22715031 DOI: 10.1002/ mnfr.201200067]
51. Jeon BT, Jeong EA, Shin HJ, Lee Y, Lee DH, Kim HJ, Kang SS, Cho GJ, Choi WS, Roh GS. Resveratrol attenuates obesityassociated peripheral and central inflammation and improves memory deficit in mice fed a high-fat diet. Diabetes 2012; 61: 1444-1454 [PMID: 22362175 DOI: 10.2337/db11-1498]
52. Li L, Hai J, Li Z, Zhang Y, Peng H, Li K, Weng X. Resveratrol modulates autophagy and NF-κB activity in a murine model for treating non-alcoholic fatty liver disease. Food Chem Toxicol 2014; 63: 166-173 [PMID: 23978414 DOI: 10.1016/ j.fct.2013.08.036]
53. Colak Y, Ozturk O, Senates E, Tuncer I, Yorulmaz E, Adali G, Doganay L, Enc FY. SIRT1 as a potential therapeutic target for treatment of nonalcoholic fatty liver disease. Med Sci Monit 2011; 17: HY5-HY9 [PMID: 21525818]
54. Deng XQ, Chen LL, Li NX. The expression of SIRT1 in nonalcoholic fatty liver disease induced by high-fat diet in rats. Liver Int 2007; 27: 708-715 [PMID: 17498258 DOI: 10.1111/ j.1478-3231.2007.01497.x]
55. Chen LL, Deng XQ, Li NX. [Effects of calorie restriction on SIRT1 expression in liver of nonalcoholic fatty liver disease: experiment with rats]. Zhonghua Yixue Zazhi 2007; 87: 1434-1437 [PMID: 17785073]
56. Costa Cdos S, Hammes TO, Rohden F, Margis R, Bortolotto JW, Padoin AV, Mottin CC, Guaragna RM. SIRT1 transcription is decreased in visceral adipose tissue of morbidly obese patients with severe hepatic steatosis. Obes Surg 2010; 20: 633-639 [PMID: 20033348 DOI: 10.1007/s11695-009-0052-z]
57. Herranz D, Muñoz-Martin M, Cañamero M, Mulero F, Martinez-Pastor B, Fernandez-Capetillo O, Serrano M. Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer. Nat Commun 2010; 1: 3 [PMID: 20975665 DOI: 10.1038/ncomms1001]
58. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010; 52: 1836-1846 [PMID: 21038418 DOI: 10.1002/hep.24001]
59. Fujii H, Kawada N. Inflammation and fibrogenesis in steatohepatitis. J Gastroenterol 2012; 47: 215-225 [PMID: 22310735 DOI: 10.1007/s00535-012-0527-x]
60. Kim CH, Park JY, Lee KU, Kim JH, Kim HK. Fatty liver is an independent risk factor for the development of Type 2 diabetes in Korean adults. Diabet Med 2008; 25: 476-481 [PMID: 18346164 DOI: 10.1111/j.1464-5491.2008.02410.x]
61. Sung KC, Jeong WS, Wild SH, Byrne CD. Combined influence of insulin resistance, overweight/obesity, and fatty liver as risk factors for type 2 diabetes. Diabetes Care 2012; 35: 717-722 [PMID: 22338098 DOI: 10.2337/dc11-1853]
62. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005; 115: 1343-1351 [PMID: 15864352 DOI: 10.1172/JCI23621]
63. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, Messadeq N, Milne J, Lambert P, Elliott P, Geny B, Laakso M, Puigserver P, Auwerx J. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006; 127: 1109-1122 [PMID: 17112576 DOI: 10.1016/ j.cell.2006.11.013]
64. Szkudelski T, Szkudelska K. Anti-diabetic effects of resveratrol. Ann N Y Acad Sci 2011; 1215: 34-39 [PMID: 21261639 DOI: 10.1111/j.1749-6632.2010.05844.x]
65. Ahn J, Cho I, Kim S, Kwon D, Ha T. Dietary resveratrol alters lipid metabolism-related gene expression of mice on an atherogenic diet. J Hepatol 2008; 49: 1019-1028 [PMID: 18930334 DOI: 10.1016/j.jhep.2008.08.012]
66. Xin P, Han H, Gao D, Cui W, Yang X, Ying C, Sun X, Hao L. Alleviative effects of resveratrol on nonalcoholic fatty liver disease are associated with up regulation of hepatic low density lipoprotein receptor and scavenger receptor class B type I gene expressions in rats. Food Chem Toxicol 2013; 52: 12-18 [PMID: 23127599 DOI: 10.1016/j.fct.2012.10.026]
67. Cho IJ, Ahn JY, Kim S, Choi MS, Ha TY. Resveratrol attenuates the expression of HMG-CoA reductase mRNA in hamsters. Biochem Biophys Res Commun 2008; 367: 190-194 [PMID: 18166149 DOI: 10.1016/j.bbrc.2007.12.140]
68. Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology 2010; 52: 774-788 [PMID: 20683968 DOI: 10.1002/hep.23719]
69. Foretz M, Guichard C, Ferré P, Foufelle F. Sterol regulatory element binding protein-1c is a major mediator of insulin action on the hepatic expression of glucokinase and lipogenesis-related genes. Proc Natl Acad Sci USA 1999; 96: 12737-12742 [PMID: 10535992]
70. Shimomura I, Bashmakov Y, Ikemoto S, Horton JD, Brown MS, Goldstein JL. Insulin selectively increases SREBP-1c mRNA in the livers of rats with streptozotocin-induced diabetes. Proc Natl Acad Sci USA 1999; 96: 13656-13661 [PMID: 10570128]
71. Yamashita H, Takenoshita M, Sakurai M, Bruick RK, Henzel WJ, Shillinglaw W, Arnot D, Uyeda K. A glucose-responsive transcription factor that regulates carbohydrate metabolism in the liver. Proc Natl Acad Sci U S A 2001; 98: 9116-9121 [PMID: 11470916 DOI: 10.1073/pnas.161284298]
72. Joseph SB, Laffitte BA, Patel PH, Watson MA, Matsukuma KE, Walczak R, Collins JL, Osborne TF, Tontonoz P. Direct and indirect mechanisms for regulation of fatty acid synthase gene expression by liver X receptors. J Biol Chem 2002; 277: 11019-11025 [PMID: 11790787 DOI: 10.1074/jbc.M111041200]
73. Repa JJ, Liang G, Ou J, Bashmakov Y, Lobaccaro JM, Shimomura I, Shan B, Brown MS, Goldstein JL, Mangelsdorf DJ. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev 2000; 14: 2819-2830 [PMID: 11090130 DOI: 10.1101/gad.844900]
74. Shang J, Chen LL, Xiao FX, Sun H, Ding HC, Xiao H. Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase. Acta Pharmacol Sin 2008; 29: 698-706 [PMID: 18501116 DOI: 10.1111/ j.1745-7254.2008.00807.x]
75. Degli Esposti D, Hamelin J, Bosselut N, Saffroy R, Sebagh M, Pommier A, Martel C, Lemoine A. Mitochondrial roles and cytoprotection in chronic liver injury. Biochem Res Int 2012; 2012: 387626 [PMID: 22745910 DOI: 10.1155/2012/387626]
76. Poulsen MM, Larsen JØ, Hamilton-Dutoit S, Clasen BF, Jessen N, Paulsen SK, Kjær TN, Richelsen B, Pedersen SB. Resveratrol up-regulates hepatic uncoupling protein 2 and prevents development of nonalcoholic fatty liver disease in rats fed a high-fat diet. Nutr Res 2012; 32: 701-708 [PMID: 23084643 DOI: 10.1016/j.nutres.2012.08.004]
77. Gómez-Zorita S, Fernández-Quintela A, Macarulla MT, Aguirre L, Hijona E, Bujanda L, Milagro F, Martínez JA, Portillo MP. Resveratrol attenuates steatosis in obese Zucker rats by decreasing fatty acid availability and reducing oxidative stress. Br J Nutr 2012; 107: 202-210 [PMID: 21733326 DOI: 10.1017/S0007114511002753]
78. Malhi H, Gores GJ. Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis 2008; 28: 360-369 [PMID: 18956292 DOI: 10.1055/s-0028-1091980]
79. Alkhouri N, Dixon LJ, Feldstein AE. Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equal. Expert Rev Gastroenterol Hepatol 2009; 3: 445-451 [PMID: 19673631 DOI: 10.1586/egh.09.32]
80. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003; 3: 23-35 [PMID: 12511873 DOI: 10.1038/ nri978]
81. Tacke F, Luedde T, Trautwein C. Inflammatory pathways in liver homeostasis and liver injury. Clin Rev Allergy Immunol 2009; 36: 4-12 [PMID: 18600481 DOI: 10.1007/ s12016-008-8091-0]
82. Bertola A, Bonnafous S, Anty R, Patouraux S, Saint-Paul MC, Iannelli A, Gugenheim J, Barr J, Mato JM, Le Marchand-Brustel Y, Tran A, Gual P. Hepatic expression patterns of inflammatory and immune response genes associated with obesity and NASH in morbidly obese patients. PLoS One 2010; 5: e13577 [PMID: 21042596 DOI: 10.1371/journal. pone.0013577]
83. Chang CC, Chang CY, Huang JP, Hung LM. Effect of resveratrol on oxidative and inflammatory stress in liver and spleen of streptozotocin-induced type 1 diabetic rats. Chin J Physiol 2012; 55: 192-201 [PMID: 22784284 DOI: 10.4077/ CJP.2011.BAA012]
84. Lee ES, Shin MO, Yoon S, Moon JO. Resveratrol inhibits dimethylnitrosamine-induced hepatic fibrosis in rats. Arch Pharm Res 2010; 33: 925-932 [PMID: 20607498 DOI: 10.1007/ s12272-010-0616-4]
85. Chávez E, Reyes-Gordillo K, Segovia J, Shibayama M, Tsutsumi V, Vergara P, Moreno MG, Muriel P. Resveratrol prevents fibrosis, NF-kappaB activation and TGF-beta increases induced by chronic CCl4 treatment in rats. J Appl Toxicol 2008; 28: 35-43 [PMID: 17429801 DOI: 10.1002/jat.1249]
86. Di Pascoli M, Diví M, Rodríguez-Vilarrupla A, Rosado E, Gracia-Sancho J, Vilaseca M, Bosch J, García-Pagán JC. Resveratrol improves intrahepatic endothelial dysfunction and reduces hepatic fibrosis and portal pressure in cirrhotic rats. J Hepatol 2013; 58: 904-910 [PMID: 23262250 DOI: 10.1016/ j.jhep.2012.12.012]
87. Bishayee A, Darvesh AS, Politis T, McGory R. Resveratrol and liver disease: from bench to bedside and community. Liver Int 2010; 30: 1103-1114 [PMID: 20557453 DOI: 10.1111/ j.1478-3231.2010.02295.x]
88. Godichaud S, Krisa S, Couronné B, Dubuisson L, Mérillon JM, Desmoulière A, Rosenbaum J. Deactivation of cultured human liver myofibroblasts by trans-resveratrol, a grapevine- derived polyphenol. Hepatology 2000; 31: 922-931 [PMID: 10733549 DOI: 10.1053/he.2000.5848]
89. Souza IC, Martins LA, Coelho BP, Grivicich I, Guaragna RM, Gottfried C, Borojevic R, Guma FC. Resveratrol inhibits cell growth by inducing cell cycle arrest in activated hepatic stellate cells. Mol Cell Biochem 2008; 315: 1-7 [PMID: 18454344 DOI: 10.1007/s11010-008-9781-x]
90. Caldwell SH, Chang CY, Nakamoto RK, Krugner-Higby L. Mitochondria in nonalcoholic fatty liver disease. Clin Liver Dis 2004; 8: 595-617, x [PMID: 15331066 DOI: 10.1016/ j.cld.2004.04.009]
91. Serviddio G, Bellanti F, Vendemiale G, Altomare E. Mitochondrial dysfunction in nonalcoholic steatohepatitis. Expert Rev Gastroenterol Hepatol 2011; 5: 233-244 [PMID: 21476918 DOI: 10.1586/egh.11.11]
92. Koek GH, Liedorp PR, Bast A. The role of oxidative stress in non-alcoholic steatohepatitis. Clin Chim Acta 2011; 412: 1297-1305 [PMID: 21514287 DOI: 10.1016/j.cca.2011.04.013]
93. Pagliassotti MJ. Endoplasmic reticulum stress in nonalcoholic fatty liver disease. Annu Rev Nutr 2012; 32: 17-33 [PMID: 22809102 DOI: 10.1146/annurev-nutr-071811-150644]
94. Bagul PK, Middela H, Matapally S, Padiya R, Bastia T, Madhusudana K, Reddy BR, Chakravarty S, Banerjee SK. Attenuation of insulin resistance, metabolic syndrome and hepatic oxidative stress by resveratrol in fructose-fed rats. Pharmacol Res 2012; 66: 260-268 [PMID: 22627169 DOI: 10.1016/ j.phrs.2012.05.003]
95. Rocha KK, Souza GA, Ebaid GX, Seiva FR, Cataneo AC, Novelli EL. Resveratrol toxicity: effects on risk factors for atherosclerosis and hepatic oxidative stress in standard and high-fat diets. Food Chem Toxicol 2009; 47: 1362-1367 [PMID: 19298841 DOI: 10.1016/j.fct.2009.03.010]
96. Franco JG, Lisboa PC, Lima NS, Amaral TA, Peixoto-Silva N, Resende AC, Oliveira E, Passos MC, Moura EG. Resveratrol attenuates oxidative stress and prevents steatosis and hypertension in obese rats programmed by early weaning. J Nutr Biochem 2013; 24: 960-966 [PMID: 22959054 DOI: 10.1016/ j.jnutbio.2012.06.019]
97. Shiozaki M, Hayakawa N, Shibata M, Koike M, Uchiyama Y, Gotow T. Closer association of mitochondria with lipid droplets in hepatocytes and activation of Kupffer cells in resveratrol-treated senescence-accelerated mice. Histochem Cell Biol 2011; 136: 475-489 [PMID: 21818579 DOI: 10.1007/ s00418-011-0847-6]
98. Palsamy P, Sivakumar S, Subramanian S. Resveratrol attenuates hyperglycemia-mediated oxidative stress, proinflam-matory cytokines and protects hepatocytes ultrastructure in streptozotocin-nicotinamide-induced experimental diabetic rats. Chem Biol Interact 2010; 186: 200-210 [PMID: 20307516 DOI: 10.1016/j.cbi.2010.03.028]
99. Palsamy P, Subramanian S. Resveratrol protects diabetic kidney by attenuating hyperglycemia-mediated oxidative stress and renal inflammatory cytokines via Nrf2-Keap1 signaling. Biochim Biophys Acta 2011; 1812: 719-731 [PMID: 21439372 DOI: 10.1016/j.bbadis.2011.03.008]
100. Ungvari Z, Bagi Z, Feher A, Recchia FA, Sonntag WE, Pearson K, de Cabo R, Csiszar A. Resveratrol confers endothelial protection via activation of the antioxidant transcription factor Nrf2. Am J Physiol Heart Circ Physiol 2010; 299: H18-H24 [PMID: 20418481 DOI: 10.1152/ajpheart.00260.2010]
101. Odegaard JI, Chawla A. Mechanisms of macrophage activation in obesity-induced insulin resistance. Nat Clin Pract Endocrinol Metab 2008; 4: 619-626 [PMID: 18838972 DOI: 10.1038/ncpendmet0976]
102. Zagotta I, Dimova EY, Funcke JB, Wabitsch M, Kietzmann T, Fischer-Posovszky P. Resveratrol suppresses PAI-1 gene expression in a human in vitro model of inflamed adipose tissue. Oxid Med Cell Longev 2013; 2013: 793525 [PMID: 23819014 DOI: 10.1155/2013/793525]
103. Gómez-Zorita S, Fernández-Quintela A, Lasa A, Hijona E, Bujanda L, Portillo MP. Effects of resveratrol on obesityrelated inflammation markers in adipose tissue of genetically obese rats. Nutrition 2013; 29: 1374-1380 [PMID: 24012391 DOI: 10.1016/j.nut.2013.04.014]
104. Olholm J, Paulsen SK, Cullberg KB, Richelsen B, Pedersen SB. Anti-inflammatory effect of resveratrol on adipokine expression and secretion in human adipose tissue explants. Int J Obes (Lond) 2010; 34: 1546-1553 [PMID: 20531350 DOI: 10.1038/ijo.2010.98]
105. Chen S, Li J, Zhang Z, Li W, Sun Y, Zhang Q, Feng X, Zhu W. Effects of resveratrol on the amelioration of insulin resistance in KKAy mice. Can J Physiol Pharmacol 2012; 90: 237-242 [PMID: 22309033 DOI: 10.1139/y11-123]
106. Sebai H, Sani M, Yacoubi MT, Aouani E, Ghanem-Boughanmi N, Ben-Attia M. Resveratrol, a red wine polyphenol, attenuates lipopolysaccharide-induced oxidative stress in rat liver. Ecotoxicol Environ Saf 2010; 73: 1078-1083 [PMID: 20089305 DOI: 10.1016/j.ecoenv.2009.12.031]
107. Farghali H, Cernỳ D, Kameníková L, Martínek J, Horínek A, Kmonícková E, Zídek Z. Resveratrol attenuates lipopolysaccharide- induced hepatitis in D-galactosamine sensitized rats: role of nitric oxide synthase 2 and heme oxygenase-1. Nitric Oxide 2009; 21: 216-225 [PMID: 19796704 DOI: 10.1016/ j.niox.2009.09.004]
108. Zhou M, Wang S, Zhao A, Wang K, Fan Z, Yang H, Liao W, Bao S, Zhao L, Zhang Y, Yang Y, Qiu Y, Xie G, Li H, Jia W. Transcriptomic and metabonomic profiling reveal synergistic effects of quercetin and resveratrol supplementation in high fat diet fed mice. J Proteome Res 2012; 11: 4961-4971 [PMID: 22916952 DOI: 10.1021/pr3004826]
109. Labbé A, Garand C, Cogger VC, Paquet ER, Desbiens M, Le Couteur DG, Lebel M. Resveratrol improves insulin resistance hyperglycemia and hepatosteatosis but not hypertriglyceridemia, inflammation, and life span in a mouse model for Werner syndrome. J Gerontol A Biol Sci Med Sci 2011; 66: 264-278 [PMID: 20974729 DOI: 10.1093/gerona/glq184]
110. Burgess TA, Robich MP, Chu LM, Bianchi C, Sellke FW. Improving glucose metabolism with resveratrol in a swine model of metabolic syndrome through alteration of signaling pathways in the liver and skeletal muscle. Arch Surg 2011; 146: 556-564 [PMID: 21739664]
111. Cho SJ, Jung UJ, Choi MS. Differential effects of low-dose resveratrol on adiposity and hepatic steatosis in diet-induced obese mice. Br J Nutr 2012; 108: 2166-2175 [PMID: 22414733 DOI: 10.1017/S0007114512000347]
112. Chen Q, Wang E, Ma L, Zhai P. Dietary resveratrol increases the expression of hepatic 7a-hydroxylase and ameliorates hypercholesterolemia in high-fat fed C57BL/6J mice. Lipids Health Dis 2012; 11: 56 [PMID: 22607622 DOI: 10.1186/1476-511X-11-56]
113. Bai Y, Mao QQ, Qin J, Zheng XY, Wang YB, Yang K, Shen HF, Xie LP. Resveratrol induces apoptosis and cell cycle arrest of human T24 bladder cancer cells in vitro and inhibits tumor growth in vivo. Cancer Sci 2010; 101: 488-493 [PMID: 20028382 DOI: 10.1111/j.1349-7006.2009.01415.x]
114. Gao M, Liu D. Resveratrol suppresses T0901317-induced hepatic fat accumulation in mice. AAPS J 2013; 15: 744-752 [PMID: 23591747 DOI: 10.1208/s12248-013-9473-7]
115. Tauriainen E, Luostarinen M, Martonen E, Finckenberg P, Kovalainen M, Huotari A, Herzig KH, Lecklin A, Mervaala E. Distinct effects of calorie restriction and resveratrol on dietinduced obesity and Fatty liver formation. J Nutr Metab 2011; 2011: 525094 [PMID: 21977315 DOI: 10.1155/2011/525094]
116. Andersen G, Burkon A, Sulzmaier FJ, Walker JM, Leckband G, Fuhst R, Erbersdobler HF, Somoza V. High dose of dietary resveratrol enhances insulin sensitivity in healthy rats but does not lead to metabolite concentrations effective for SIRT1 expression. Mol Nutr Food Res 2011; 55: 1197-1206 [PMID: 21732533 DOI: 10.1002/mnfr.201100292]
117. Timmers S, Konings E, Bilet L, Houtkooper RH, van de Weijer T, Goossens GH, Hoeks J, van der Krieken S, Ryu D, Kersten S, Moonen-Kornips E, Hesselink MK, Kunz I, Schrauwen-Hinderling VB, Blaak EE, Auwerx J, Schrauwen P. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab 2011; 14: 612-622 [PMID: 22055504 DOI: 10.1016/j.cmet.2011.10.002]
118. Poulsen MM, Vestergaard PF, Clasen BF, Radko Y, Christensen LP, Stødkilde-Jørgensen H, Møller N, Jessen N, Pedersen SB, Jørgensen JO. High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes 2013; 62: 1186-1195 [PMID: 23193181 DOI: 10.2337/db12-0975]
119. Yoshino J, Conte C, Fontana L, Mittendorfer B, Imai S, Schechtman KB, Gu C, Kunz I, Rossi Fanelli F, Patterson BW, Klein S. Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance. Cell Metab 2012; 16: 658-664 [PMID: 23102619 DOI: 10.1016/j.cmet.2012.09.015]
120. Smoliga JM, Colombo ES, Campen MJ. A healthier approach to clinical trials evaluating resveratrol for primary prevention of age-related diseases in healthy populations. Aging (Albany NY) 2013; 5: 495-506 [PMID: 24073437]